Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Litigation topic
No spam. Unsubscribe anytime.
Maryland Supreme Court decision cut Baltimore’s expected opioid settlement award by $152M, officials say
Summary
City presenters told the council Baltimore pursued independent litigation rather than joining global settlements and that the McKesson/Sincora trial and Maryland Supreme Court rulings reduced the city's earlier award by $152 million.
Sarah Whaley told the committee that Baltimore pursued an independent litigation strategy instead of joining global agreements with states and other jurisdictions. She said that approach produced awards but that a trial in the McKesson and Sincora matter was appealed and later reversed by the Maryland Supreme Court.
"Following the trial and the ... decisions, appeals were filed, and so that case moved up to the Maryland Supreme Court," Whaley said, and the reversal "ultimately reduced our total funding amount by $152,000,000." Officials said the reduction is a disappointment but that they are managing the fund based on the dollars currently in hand and the city's ongoing allocations and commitments.
Council members asked whether the city has received the funds it will receive to date; presenters said the amounts shown on the public dashboard reflect awards less litigation and court costs and that the city has received what it will for now.
